Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Title
Intervention Indication Therapeutic Area Year Actions
Nivolumab in combination with rucaparib for chemotherapy naive metastatic castration-resistant prostate cancer Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Rucaparib (Rubraca) for platinum-sensitive, high-grade serous or endometrioid epithelial ovarian cancer, primary peritoneal or fallopian tube cancer Rucaparib (Rubraca; PF-1367338) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Rucaparib maintenance therapy for ovarian, fallopian tube or primary peritoneal cancer after frontline platinum-based chemotherapy Rucaparib (Rubraca; PF-1367338) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications